share_log

PetMed Express Analyst Ratings

PetMed Express Analyst Ratings

PetMed Express
Benzinga ·  2023/07/28 00:49
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
07/27/2023 18.63% Morgan Stanley $17 → $17 Reiterates Underweight → Underweight
05/25/2023 39.57% Lake Street → $20 Initiates Coverage On → Buy
03/23/2023 18.63% Morgan Stanley $18 → $17 Maintains Underweight
11/08/2022 25.61% Morgan Stanley $19 → $18 Maintains Underweight
07/26/2022 32.59% Morgan Stanley $20 → $19 Maintains Underweight
05/10/2022 39.57% Morgan Stanley $21 → $20 Maintains Underweight
01/25/2022 46.55% Morgan Stanley $25 → $21 Maintains Underweight
01/20/2022 123.31% Sidoti & Co. → $32 Upgrades Neutral → Buy
11/18/2021 74.46% Morgan Stanley → $25 Initiates Coverage On → Underweight
10/01/2021 95.39% Jefferies → $28 Initiates Coverage On → Hold
06/03/2021 172.16% Sidoti & Co. → $39 Downgrades Buy → Neutral
03/05/2021 Sidoti & Co. Upgrades Neutral → Buy
08/19/2020 186.11% Sidoti & Co. $37 → $41 Upgrades Neutral → Buy
02/24/2020 Sidoti & Co. Downgrades Buy → Neutral
10/17/2019 39.57% Craig-Hallum $15 → $20 Maintains Hold
08/16/2019 Craig-Hallum Downgrades Buy → Hold
日期 上行/下行 分析公司 目標價格變動 評級變動 之前/當前的評級
07/27/2023 18.63% 摩根士丹利 17 美元 → 17 美元 重申 體重過輕 → 體重不足
05/25/2023 39.57% 湖街 → 20 美元 啓動覆蓋開啓 → 購買
03/23/2023 18.63% 摩根士丹利 18 美元 → 17 美元 維護 體重不足
2022 年 8 月 11 日 25.61% 摩根士丹利 19 美元 → 18 美元 維護 體重不足
07/26/2022 32.59% 摩根士丹利 20 美元 → 19 美元 維護 體重不足
05/10/2022 39.57% 摩根士丹利 21 美元 → 20 美元 維護 體重不足
01/25/2022 46.55% 摩根士丹利 25 美元 → 21 美元 維護 體重不足
01/20/2022 123.31% Sidoti & Co. → 32 美元 升級 中性 → 買入
11/18/2021 74.46% 摩根士丹利 → 25 美元 啓動覆蓋開啓 → 體重不足
2021 年 1 月 10 日 95.39% 傑富瑞 → 28 美元 啓動覆蓋開啓 → 按住
06/03/2021 172.16% Sidoti & Co. → 39 美元 降級 買入 → 中性
03/05/2021 Sidoti & Co. 升級 中性 → 買入
2020 年 8 月 19 日 186.11% Sidoti & Co. 37 美元 → 41 美元 升級 中性 → 買入
2020 年 2 月 24 日 Sidoti & Co. 降級 買入 → 中性
10/17/2019 39.57% Craig-Hallum 15 美元 → 20 美元 維護 保持
2019 年 8 月 16 日 Craig-Hallum 降級 買入 → 持有

What is the target price for PetMed Express (PETS)?

PetMed Express (PETS) 的目標價格是多少?

The latest price target for PetMed Express (NASDAQ: PETS) was reported by Morgan Stanley on July 27, 2023. The analyst firm set a price target for $17.00 expecting PETS to rise to within 12 months (a possible 18.63% upside). 4 analyst firms have reported ratings in the last year.

摩根士丹利於2023年7月27日公佈了PetMed Express(納斯達克股票代碼:PETS)的最新目標股價。這家分析公司將目標股價定爲17.00美元,預計PETS將在12個月內升至18.63%(可能上漲18.63%)。去年有4家分析公司公佈了評級。

What is the most recent analyst rating for PetMed Express (PETS)?

分析師對PetMed Express(PETS)的最新評級是多少?

The latest analyst rating for PetMed Express (NASDAQ: PETS) was provided by Morgan Stanley, and PetMed Express reiterated their underweight rating.

PetMed Express(納斯達克股票代碼:PETS)的最新分析師評級由摩根士丹利提供,PetMed Express重申了他們的減持評級。

When is the next analyst rating going to be posted or updated for PetMed Express (PETS)?

PetMed Express(PETS)的下一個分析師評級何時公佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PetMed Express, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PetMed Express was filed on July 27, 2023 so you should expect the next rating to be made available sometime around July 27, 2024.

分析師在進行了廣泛的研究(包括瀏覽公開財務報表、與PetMed Express的高管和客戶交談以及聽取財報電話會議)後得出股票評級。大多數分析師每三個月進行一次評級,因此每家公司每年應該獲得4個評級。PetMed Express的最後一次評級是在2023年7月27日提交的,因此你應該預計下一個評級將在2024年7月27日左右公佈。

Is the Analyst Rating PetMed Express (PETS) correct?

分析師對 PetMed Express (PETS) 的評級正確嗎?

While ratings are subjective and will change, the latest PetMed Express (PETS) rating was a reiterated with a price target of $17.00 to $17.00. The current price PetMed Express (PETS) is trading at is $14.33, which is out of the analyst's predicted range.

儘管評級是主觀的,會發生變化,但最新的PetMed Express(PETS)評級得到了重申,目標股價爲17.00美元至17.00美元。PetMed Express(PETS)目前的交易價格爲14.33美元,超出了分析師的預測區間。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論